Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression

Weicheng Wang(Nanjing Medical University), Yanhong Gu(Nanjing Medical University), Jian Gao(Hebei Medical University), Wenjie Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongqian Shu(Jiangsu Cancer Hospital), Zan Fu(Jiangsu Province Hospital), Wen Liu(Tongji University), Qiang Xu(China Pharmaceutical University), Lele Li(Nantong University), Yang Sun(Nanjing Drum Tower Hospital)
Biochemical Pharmacology
October 6, 2016
10.1016/j.bcp.2016.09.024
Cited by 91

Related Papers

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner
|Oncogene|2019|265
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
|癌症：英文版|2021|207
Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH
|Redox Biology|2020|201
Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis
|Cell Death and Disease|2019|193